QX029N
/ Qyuns Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 31, 2025
A randomized, open, parallel phase I trial to Investigate the pharmacokinetics, pharmacodynamics, immunogenicity, safety, and tolerability of QX029N Injection and to compare the pharmacokinetic characteristics of QX029N Injection with QX005N Injection in healthy subjects
(ChiCTR)
- P1 | N=152 | Not yet recruiting | Sponsor: Hangzhou First People's Hospital; Hangzhou First People's Hospital
New P1 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
1 to 1
Of
1
Go to page
1